Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III single-arm study of subcutaneous 4‑month sustained‑release triptorelin in prostate cancer
2006-001511-30Phase 3Completed
- Sponsor
- Ipsen
- Start
- Jul 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of triptorelin in prostate cancer (PCa), sponsored by Ipsen. Primary endpoints: Maintenance of medical castration at Day 240 and Maintenance of medical castration at Day 120 (Part A). Started Jul 2006; status: completed.
02
Drugs
triptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-001511-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001511-30.